radium has been researched along with Disease Exacerbation in 27 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (3.70) | 29.6817 |
| 2010's | 22 (81.48) | 24.3611 |
| 2020's | 4 (14.81) | 2.80 |
| Authors | Studies |
|---|---|
| Frank, SJ; Heinrich, D; Keizman, D; Li, R; Mariados, N; Méndez Vidal, MJ; Nordquist, LT; Peer, A; Procopio, G; Pulkkanen, K; Rosenbaum, E; Sartor, O; Severi, S; Thellenberg Karlsson, C; Trandafir, L; Trigo, J; Wagner, V | 1 |
| Borsellino, N; Costa, R; Gebbia, V; Licari, M; Murabito, A; Princiotta, A; Sanfilippo, C; Scalici Gesolfo, C; Serretta, V; Tripoli, V; Valerio, MR; Verderame, F | 1 |
| Cindolo, L; Costa, R; De Vincentis, G; Farcomeni, A; Frantellizzi, V; Licari, M; Mascia, M; Nuvoli, S; Pontico, M; Spanu, A | 1 |
| Antonarakis, ES; Caldwell, T; Carducci, MA; Deek, MP; Denmeade, S; Deville, C; DeWeese, TL; Dipasquale, S; Dudley, S; Eisenberger, MA; Gorin, MA; Greco, SC; Hasan, H; Hobbs, RF; Huang, J; Kiess, AP; Leitzel, J; Malek, R; Markowski, M; Paller, CJ; Phillips, R; Pienta, KJ; Pomper, MG; Powell, J; Radwan, N; Rowe, SP; Song, DY; Thompson, E; Tran, PT; Wang, H; Wendler, D | 1 |
| Casarin, S; Dondossola, E | 1 |
| Devos, G; Everaerts, W; Goffin, K; Joniau, S; Pans, S; Schillebeeckx, L; Tosco, L; Van Poppel, H | 1 |
| Izumi, K; Kadono, Y; Kitagawa, Y; Konaka, H; Mizokami, A | 1 |
| Hinz, S | 1 |
| Coel, MN; Kwee, SA; Lim, J | 1 |
| George, DJ | 1 |
| Arranz, JA; Carles, J; Castellano, D; Del Alba, AG; Donas, JG; Esteban, E; Germà, JR; Hernando, S; Laínez, N; León, L; López-Brea, M; López-Criado, P; Maroto, P; Mellado, B; Méndez, MJ; Moretones, C; Pérez-Gracia, JL; Pérez-Valderrama, B; Pinto, Á; Reynés, G; Sáez, MI | 1 |
| Coleman, RE; Den, R; Logothetis, C; Morris, MJ | 1 |
| Bruland, ØS; Herlofson, BB; Kjølle, GK; Løndalen, AM; Westgaard, KL | 1 |
| Arranz, JÁ; Carles, J; Castellano, D; González Del Alba, A; Jimenez, J; López, C; Manneh, R; Mellado, B; Méndez-Vidal, MJ; Morales-Barrera, R; Perez-Gracia, JL; Porras, I; Saez, MI; Sepúlveda, JM; Suárez, C | 1 |
| Carles, J; Gillessen, S; Heidenreich, A; Heinrich, D; Keizman, D; Miller, K; Nilsson, S; O'Sullivan, JM; Reeves, J; Saad, F; Seger, M; Wirth, M | 1 |
| Anand, A; Anand, M; Armstrong, AJ; Chin, BB; George, DJ; McNamara, MA; Oldan, J; Oyekunle, T; Ritz, M; Shantzer, L | 1 |
| Anand, M; Armstrong, AJ; Davies, C; Foo, WC; George, DJ; Gerber, D; Giannakakou, P; Gregory, SG; Gupta, S; Halabi, S; Healy, P; Kemeny, G; Leith, B; Ribar, T; Rothwell, C; Somarelli, JA; Spritzer, C; Ware, K; Wood, K; Zalutsky, MR; Zhang, J | 1 |
| Challa, S; Conti, PS; Jadvar, H; Quinn, DI | 1 |
| Chopra, S; Rashid, P | 1 |
| Crawford, ED; Higano, CS; Hussain, M; Petrylak, DP; Shore, ND | 1 |
| Coel, MN; Kwee, SA; Lee, J; Lee, KH; Sato, MM | 1 |
| Leeman, J; Morris, MJ; Osborne, JR; Rebeiz, K; Rivera, A; Spratt, DE; Zelefsky, MJ; Zumsteg, ZS | 1 |
| Aarts, MJ; Badrising, SK; Bergman, AM; Coenen, JL; de Jong, IJ; Gelderblom, H; Haanen, JB; Hamberg, P; Kerver, ED; Los, M; van den Berg, HP; van den Eertwegh, AJ; van der Noort, V; van Oort, IM; van Voorthuizen, T; Vrijaldenhoven, S | 1 |
| Cotogna, PM; Fiorillo, M; Jacene, HA; Jacobus, S; Ledet, EM; McKay, RR; Sartor, O; Steinberger, AE; Taplin, ME | 1 |
| Concepcion, RS; Crawford, ED; Finkelstein, SE; Gomella, LG; Keane, TE; Koo, PJ; O'Sullivan, JM; Petrylak, DP; Saad, F; Shore, N; Sieber, P; Slovin, SF; Stone, NN; Tombal, B; Vogelzang, NJ; Yu, EY | 1 |
| Liepe, K | 1 |
8 review(s) available for radium and Disease Exacerbation
| Article | Year |
|---|---|
Therapies for castration-resistant prostate cancer in a new era: The indication of vintage hormonal therapy, chemotherapy and the new medicines.
Topics: Abiraterone Acetate; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Neoplasms; Disease Progression; Docetaxel; Humans; Japan; Male; Neoplasm Recurrence, Local; Nitriles; Phenylthiohydantoin; Prognosis; Progression-Free Survival; Prostatic Neoplasms, Castration-Resistant; Radium; Taxoids | 2017 |
[Monitoring of treatment for metastatic castration-resistant prostate cancer].
Topics: Abiraterone Acetate; Benzamides; Biomarkers, Tumor; Combined Modality Therapy; Disease Progression; Docetaxel; Humans; Male; Neoplastic Cells, Circulating; Nitriles; Outcome and Process Assessment, Health Care; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Radium; Taxoids | 2017 |
Current perspectives on bone metastases in castrate-resistant prostate cancer.
Topics: Animals; Biomarkers, Tumor; Bone Neoplasms; Disease Models, Animal; Disease Progression; Humans; Male; Mice; Neoplasm Metastasis; Prostatic Neoplasms, Castration-Resistant; Radium; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2018 |
Management of castration-resistant (advanced) prostate cancer (CRPC): rationale, progress and future directions.
Topics: Androgen Receptor Antagonists; Antineoplastic Agents; Australia; Disease Progression; Docetaxel; General Practice; Humans; Male; Neoplasm Metastasis; Orchiectomy; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Taxoids | 2015 |
Treating Patients with Metastatic Castration Resistant Prostate Cancer: A Comprehensive Review of Available Therapies.
Topics: Androgen Antagonists; Androstenes; Antineoplastic Agents; Benzamides; Disease Progression; Docetaxel; Humans; Male; Neoplasm Metastasis; Neoplasm Staging; Nitriles; Orchiectomy; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Survival Rate; Taxoids; Tissue Extracts | 2015 |
Radium-223 (Ra-223) Re-Treatment (Re-tx): First Experience From an International, Multicenter, Prospective Study in Patients (Pts) With Castration-Resistant Prostate Cancer and Bone Metastases (mCRPC).
Topics: Antineoplastic Agents; Bone Neoplasms; Chemoradiotherapy; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Disease Progression; Humans; Male; Multicenter Studies as Topic; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Retreatment; Treatment Outcome | 2016 |
The Role of Therapeutic Layering in Optimizing Treatment for Patients With Castration-resistant Prostate Cancer (Prostate Cancer Radiographic Assessments for Detection of Advanced Recurrence II).
Topics: Androgens; Androstenes; Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Disease Progression; Humans; Immunotherapy; Male; Neoplasm Metastasis; Neoplasm Recurrence, Local; Nitriles; Phenylthiohydantoin; Practice Guidelines as Topic; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Treatment Outcome | 2017 |
Alpharadin, a 223Ra-based alpha-particle-emitting pharmaceutical for the treatment of bone metastases in patients with cancer.
Topics: Alpha Particles; Animals; Bone Neoplasms; Clinical Trials, Phase III as Topic; Disease Progression; Humans; Neoplasms; Quality of Life; Radiopharmaceuticals; Radium; Survival Rate | 2009 |
5 trial(s) available for radium and Disease Exacerbation
| Article | Year |
|---|---|
Re-treatment with radium-223: 2-year follow-up from an international, open-label, phase 1/2 study in patients with castration-resistant prostate cancer and bone metastases.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Bone Neoplasms; Disease Progression; Follow-Up Studies; Humans; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Survival Rate | 2019 |
A phase II randomized trial of RAdium-223 dichloride and SABR Versus SABR for oligomEtastatic prostate caNcerS (RAVENS).
Topics: Adult; Aged; Aged, 80 and over; Animals; Bone Neoplasms; Chemoradiotherapy; Clinical Trials, Phase II as Topic; Disease Progression; Humans; Male; Middle Aged; Progression-Free Survival; Prostatic Neoplasms; Radioisotopes; Radiosurgery; Radium; Randomized Controlled Trials as Topic; Young Adult | 2020 |
Radium-223 international early access program: results from the Spanish subset.
Topics: Aged; Aged, 80 and over; Bone Neoplasms; Disease Progression; Disease-Free Survival; Humans; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Spain | 2018 |
Radium-223 in asymptomatic patients with castration-resistant prostate cancer and bone metastases treated in an international early access program.
Topics: Aged; Aged, 80 and over; Androstenes; Bone Neoplasms; Disease Progression; Disease-Free Survival; Docetaxel; Drug-Related Side Effects and Adverse Reactions; Humans; Male; Middle Aged; Neoplasm Metastasis; Proportional Hazards Models; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Treatment Outcome | 2019 |
Pharmacodynamic study of radium-223 in men with bone metastatic castration resistant prostate cancer.
Topics: Aged; Alkaline Phosphatase; Biomarkers, Tumor; Biopsy; Bone and Bones; Bone Neoplasms; Cadherins; Core Binding Factor Alpha 1 Subunit; Disease Progression; Gene Expression; Humans; Male; Molecular Targeted Therapy; Neoplastic Cells, Circulating; Osteonectin; Osteopontin; Prostate; Prostatic Neoplasms, Castration-Resistant; Radium; Survival Analysis; Tumor Microenvironment | 2019 |
14 other study(ies) available for radium and Disease Exacerbation
| Article | Year |
|---|---|
Radium-223 treatment in castration resistant bone metastatic prostate cancer. Should be the primary tumor always treated?
Topics: Aged; Antineoplastic Agents; Bone Neoplasms; Chemoradiotherapy, Adjuvant; Disease Progression; Follow-Up Studies; Humans; Male; Neoplasm Grading; Prognosis; Prostate; Prostatectomy; Prostatic Neoplasms, Castration-Resistant; Radiopharmaceuticals; Radium; Survival Analysis; Treatment Outcome | 2019 |
Primary Radical Prostatectomy or Ablative Radiotherapy as Protective Factors for Patients With mCRPC Treated With Radium-223 Dichloride: An Italian Multicenter Study.
Topics: Aged; Aged, 80 and over; Brachytherapy; Combined Modality Therapy; Disease Progression; Follow-Up Studies; Humans; Italy; Male; Middle Aged; Prognosis; Prostatectomy; Prostatic Neoplasms, Castration-Resistant; Protective Factors; Radioisotopes; Radium; Retrospective Studies; Survival Rate | 2020 |
An agent-based model of prostate Cancer bone metastasis progression and response to Radium223.
Topics: Animals; Bone Neoplasms; Brachytherapy; Cell Line, Tumor; Computer Simulation; Disease Progression; Humans; Intravital Microscopy; Male; Mice; Microscopy, Fluorescence; Models, Biological; Prostatic Neoplasms; Radiation Tolerance; Radium; Tibia; Xenograft Model Antitumor Assays | 2020 |
Radium-223 in patients with prostate specific antigen (PSA) progression and without clinical metastases following maximal local therapy: A pilot study.
Topics: Aged; Antineoplastic Agents; Disease Progression; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Pilot Projects; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms; Radioisotopes; Radium | 2022 |
Soft Tissue Response on 18F-Fluorocholine PET/CT in Metastatic Castrate-Resistant Prostate Cancer Treated With 223Ra-Dichloride: A Possible Abscopal Effect?
Topics: Aged, 80 and over; Choline; Disease Progression; Humans; Male; Neoplasm Metastasis; Positron Emission Tomography Computed Tomography; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Treatment Outcome | 2017 |
Optimal use of radium-223 in patients with metastatic castration-resistant prostate cancer.
Topics: Bone Neoplasms; Clinical Decision-Making; Combined Modality Therapy; Disease Progression; Humans; Male; Neoplasm Metastasis; Neoplasm Staging; Patient Selection; Prostatic Neoplasms, Castration-Resistant; Radium; Symptom Assessment; Treatment Outcome | 2017 |
Osteonecrosis of the Jaw in a Patient With Bone Metastatic Prostate Cancer After Long-term Bisphosphonate Treatment With Severe Deterioration Following Radium-223.
Topics: Aged; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Neoplasms; Diphosphonates; Disease Progression; Fatal Outcome; Humans; Male; Prostatic Neoplasms; Radium | 2018 |
Circulating Tumor Cells as a Biomarker of Survival and Response to Radium-223 Therapy: Experience in a Cohort of Patients With Metastatic Castration-Resistant Prostate Cancer.
Topics: Aged; Aged, 80 and over; Bone Neoplasms; Cell Count; Disease Progression; Follow-Up Studies; Humans; Injections, Intravenous; Male; Neoplastic Cells, Circulating; Prognosis; Progression-Free Survival; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radiotherapy Dosage; Radium | 2018 |
Patterns of response and progression in bone and soft tissue during and after treatment with radium-223 for metastatic castrate-resistant prostate cancer.
Topics: Adult; Aged; Aged, 80 and over; Bone Neoplasms; Disease Progression; Humans; Male; Middle Aged; Prognosis; Prostatic Neoplasms, Castration-Resistant; Radium; Retrospective Studies; Soft Tissue Neoplasms; Treatment Outcome | 2019 |
One-Year Postapproval Clinical Experience with Radium-223 Dichloride in Patients with Metastatic Castrate-Resistant Prostate Cancer.
Topics: Aged; Aged, 80 and over; Alkaline Phosphatase; Antineoplastic Agents; Bone Neoplasms; Disease Progression; Humans; Male; Middle Aged; Pain; Pain Measurement; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Retrospective Studies; Treatment Outcome | 2015 |
Prediction of PSA Progression in Castration-Resistant Prostate Cancer Based on Treatment-Associated Change in Tumor Burden Quantified by 18F-Fluorocholine PET/CT.
Topics: Aged; Androgen Antagonists; Antineoplastic Agents; Cancer Vaccines; Choline; Combined Modality Therapy; Disease Progression; Humans; Kaplan-Meier Estimate; Male; Positron Emission Tomography Computed Tomography; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radiopharmaceuticals; Radium; Tissue Extracts; Tumor Burden; Whole Body Imaging | 2016 |
Radium-223 outcomes after multiple lines of metastatic castration-resistant prostate cancer therapy in clinical practice: implication of pre-treatment spinal epidural disease.
Topics: Aged; Aged, 80 and over; Brachytherapy; Combined Modality Therapy; Disease Progression; Epidural Neoplasms; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Prostatic Neoplasms, Castration-Resistant; Radium; Retrospective Studies; Treatment Outcome | 2016 |
Enzalutamide as a Fourth- or Fifth-Line Treatment Option for Metastatic Castration-Resistant Prostate Cancer.
Topics: Abdominal Neoplasms; Abiraterone Acetate; Aged; Antineoplastic Agents; Benzamides; Bone Neoplasms; Disease Progression; Disease-Free Survival; Docetaxel; Humans; Lymphatic Metastasis; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Retreatment; Retrospective Studies; Survival Rate; Taxoids | 2016 |
Radium-223 Use in Clinical Practice and Variables Associated With Completion of Therapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Disease Progression; Drug Administration Schedule; Humans; Male; Middle Aged; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Radioisotopes; Radium; Retrospective Studies; Survival Analysis; Tissue Extracts; Treatment Outcome | 2017 |